Web Scouter
Back to News
Security News

Genentech Brings Pertuzumab Biosimilar Fight to the ITC

UnknownMar 3, 2026(16 days ago)

Genentech filed a complaint against Biocon at the ITC regarding a proposed biosimilar.

On February 27, 2026, Genentech filed a Section 337 complaint at the U.S. International Trade Commission (ITC) targeting Biocon’s proposed pertuzumab biosimilar, BMAB 1500/PERT-IJS, which references Genentech’s PERJETA®.... By: Goodwin

Related News

CISA urges US orgs to secure Microsoft Intune systems after Stryker breach

Unknownabout 2 hours ago

How Ceros Gives Security Teams Visibility and Control in Claude Code

Unknownabout 2 hours ago

Raven Emerges From Stealth With $20 Million in Funding

Unknownabout 3 hours ago

Get Personalized Alerts

Track vendors and receive alerts when security incidents affect your supply chain.

What We Monitor

Security Incidents

Data breaches, ransomware, and unauthorized access

Vulnerabilities

CVEs and vendor security advisories

Compliance Updates

Regulatory changes and certification news

Legal News

Privacy laws and enforcement actions

Vendor Directory

Browse our directory of SaaS vendors with security documentation and compliance information.